In a world of strict FDA regulation of cigars, there will likely be some process where companies trade or sell the rights to FDA-approved blends to others.
Micallef Cigars is planning an ambitious project that would allow for just that, but on a larger and more efficient scale.
For more information about FDA testing and approval of cigar blends, click here.
In short, companies would be asked to pay a membership fee and to provide a license for at least some of their FDA-approved blends, i.e. predicate blends, to PredX. In exchange, they would be able to access the full library of PredX-licensed blends, removing both the need to individually buy a license for another predicate blend and the associated legal fees.
The original companies would still own the full rights to the blends and would be able to sell additional licenses to non-members, but PredX would retain a perpetual license, which its members could use.
Dan Thompson, president of Micallef Cigars, repeatedly stressed to halfwheel that what PredX will become should be up to its members, not Micallef. As such, the company has a broad framework of how it might work, but specifics such as how many blends a member would need to license to PredX, membership fees and other specifics will be determined in the coming months.
The organization has laid out a brief timeline of how it plans on operating before the current May 2020 substantial equivalence deadline, though much of that time will be spent determining what the organization should look like.
- December/January — Recruit companies to PredX.
- February — Finalize PredX framework including the election of a board of members.
- March — Begin predicate process.
- April — Finalize database of predicate liccenses.
Micallef has filed to create PredX as a 501(c)(3) non-profit and has committed to covering the operational costs for the first year.
Thompson told halfwheel he believes there could be two classes of members. One would be companies that would provide FDA-approved predicate blends, those companies would be able to access the PredX library royalty-free. Another would be for companies that would be unable to provide FDA-approved blends—likely because the companies are too new—in which a company would likely need to pay a fee for each use of a predicate blend.
FDA recognizes the concept of a company selling the right to use an approved blend. The process is mentioned extensively throughout the 2016 deeming regulations.
For its part, Micallef says that it plans to provide its FDA-approved predicate blends, in their entirety, to PredX.
Thompson said that other companies have been approached about joining PredX and the group has received varying levels of interest.